SM
ATOS icon

SG3 Management’s Atossa Therapeutics ATOS Stock Holding History

SG3 Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,667
Closed -$40K – 953
2021
Q4 		$40K Hold
1,667
– – ﹤0.01% 967
2021
Q3 		$82K Hold
1,667
– – ﹤0.01% 882
2021
Q2 		$158K Hold
1,667
– – 0.01% 856
2021
Q1 		$53K Buy
+1,667
New +$60.9K ﹤0.01% 1088

Other funds holding ATOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SG3 Management's ATOS Position: Q3 2021 in Review

SG3 Management sold out of Atossa Therapeutics (ATOS) in Q3 2021, closing a stake of 167 shares — an estimated $9.71K sold.

SG3 Management first reported a position in ATOS in Q1 2021 and held it in 2 quarters. The position peaked at $16K in Q2 2021. 93 funds tracked by Wall St. Rank hold ATOS as of Q3 2021.

  • SG3 Management reported no remaining Atossa Therapeutics position as of Q3 2021 after selling out during the quarter.
  • SG3 Management sold 167 Atossa Therapeutics shares in Q3 2021, an estimated $9.71K.
  • SG3 Management first reported a position in Atossa Therapeutics in Q1 2021 and held it in 2 quarters.
  • SG3 Management's Atossa Therapeutics position peaked at $16K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.